Navigation Links
Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Date:1/31/2008

SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New York on Wednesday, February 6, 2008 at 1:00 p.m. ET / 10:00 a.m. PT. Mark G. Foletta, Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, will be providing a corporate overview.

The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,900 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Diego, CA (PRWEB) October 30, 2014 ... announced today that they have manually curated public data ... and non profit customers. the data is now ... manually curates and unifies public and internal data sources ... value and knowledge out of the data that becomes ...
(Date:10/30/2014)... UAE (PRWEB) October 30, 2014 Grace Century ... Dr. James A. Manganello, Chairman of the Board, to the ... Bahamas. The appointment was made by the Ministry of ... September 24th, 2014. , More than a year ... Research Bill , Prime Minister Perry Christie said the government ...
(Date:10/30/2014)... 2014) – The severe flooding that devastated a wide ... destructive if the bridges, roads and other infrastructure had ... from the University of Colorado Denver. , "People need ... Jimmy Kim, PhD, associate professor of structural engineering at ... and lead author the study. "There is an assumption ...
(Date:10/27/2014)... 27, 2014 Kalorama Information says that PCR ... in the United States and ... market researcher said the FDA,s Emergency Use Authorization (EUA) to ... for the detection of the Ebola virus was an ... routinely assess the IVD industry and its biennial survey ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3CU Denver study says upgrading infrastructure could reduce flood damage 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3
... Force History Appointed to Highest Noncommissioned Officer Position , ... announced today that Retired Chief Master Sergeant of the Air ... Vice President of Strategic Partnerships. MicroTech is one of ... the U.S. In his new role, McKinley will provide strategic ...
... achieves similar efficacy to daily injections of follitropin beta ... Study , , AMSTERDAM, July 1 Schering-Plough ... from the Phase III ENGAGE clinical trial demonstrating that ... class of sustained follicle stimulants, achieved similar efficacy to ...
... Inc., a subsidiary of Eisai Corporation of North America, ... to express and develop therapeutic monoclonal antibodies for the ... disease. , , Under the terms of the ... (SEP(TM)) technology and its expertise to produce and develop ...
Cached Biology Technology:Air Force Chief Master Sergeant Rod McKinley (U.S. Air Force Retired) Joins MicroTech as Vice President of Strategic Partnerships 2Air Force Chief Master Sergeant Rod McKinley (U.S. Air Force Retired) Joins MicroTech as Vice President of Strategic Partnerships 3Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 2Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 3Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 4Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 5Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 6Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 7Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 8Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 9Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 2Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 3
(Date:10/29/2014)... suggesting air pollutants released by unconventional oil and gas ... is published today in the open access journal ... and formaldehyde were found. The study is the first ... live near production sites and could be used to ... gas come from reserves that do not readily flow ...
(Date:10/29/2014)... registration is open for the Society ... Meeting. SIR 2015 is the one place ... and related health care professionals can come ... science and technologies being presented, discussed and ... in minimally invasive, image-guided medicine, SIR 2015 ...
(Date:10/29/2014)... the safety of nanoparticles is all the rage. Thousands ... examining the question of whether titanium dioxide nanoparticles from ... the body, whether carbon nanotubes from electronic products are ... be or whether nanoparticles in food can get into ... interest is great, research funds are flowing – and ...
Breaking Biology News(10 mins):Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3SIR 2015: Interventional radiology shapes tomorrow's medicine 2Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3
... an extract of an exotic type of seaweed, say British ... used to increase the fibre content of cakes, burgers and ... fat and a low degree of healthy nutrients, say the ... publish their findings in the academic journal Critical Reviews in ...
... artificial shark skin could help ships sailing smoothly. The ... hulls is a major cause of increased energy costs ... design that prevents this so called 'bio-fouling'. , Ralph ... is presenting his work on the application of artificial ...
... us from disease, destroying invading microbes with a swarm of attacking ... ganging up on normal tissues in our body and wreaking havoc. ... the inner ear, home to the tiny, delicate structures that allow ... the ability to hear in one or both ears. Some might ...
Cached Biology News:Seaweed could make junk food healthier 2New Lab Research May Help Those Deafened By Immune System Attack 2New Lab Research May Help Those Deafened By Immune System Attack 3New Lab Research May Help Those Deafened By Immune System Attack 4
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
... These are just some the things youll ... of Protein-Protein Interactions, edited by Erica Golemis, One ... skillfully edited compilation of topics in protein interaction ... text that must be a part of your ...
... Persistent Analysis Environment 2) Dot plot, ... 3) Software Compensation 4) Cell Cycle ... Platform 7) Intelligent batch generation of graphs ... 9) Single drag-and-drop operations to perform complex ...
Eagle's Ham's amino acids; EHAA...
Biology Products: